Vanda Pharmaceuticals (VNDA): רווח נקי למניה ב-12 החודשים האחרונים
Vanda Pharmaceuticals (VNDA) generates revenue from the sale of patented treatments for sleep disorders and schizophrenia. The trailing 12-month EPS reflects profitability trends, where -4.61 represents the metric's baseline. Patent protection shields margins from generics, while an academic approach to hiring neurobiologists with long-term options ensures sustainable business growth within the neuropsychiatry niche.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%A0%D7%A7%D7%99%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%90%D7%97%D7%AA%20%D7%91%D7%A9%D7%A0%D7%99%D7%9D%20%D7%A2%D7%A9%D7%A8%20%D7%94%D7%97%D7%95%D7%93%D7%A9%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_VNDA_-_Vanda-Pharmaceuticals_-_Net-earnings-per-one-share-for-the-last-twelve-months "רווח נקי למניה (EPS TTM) Vanda Pharmaceuticals (VNDA): לתקופה 04.07.2022 - 14.11.2026 | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Vanda Pharma (VNDA)
Dynamic monitoring of earnings per share minimizes the risks of decision-making based on outdated quarterly data, which is critical for Vanda Pharmaceuticals (VNDA) given its stable scientific staff and protected patent portfolio. An analysis of fundamental TTM earnings per share allows for an assessment of the real efficiency of intellectual resource capitalization, dividing total net income by the number of securities to determine the true return on equity.
